483 related articles for article (PubMed ID: 16960150)
1. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
Mrózek K; Marcucci G; Paschka P; Whitman SP; Bloomfield CD
Blood; 2007 Jan; 109(2):431-48. PubMed ID: 16960150
[TBL] [Abstract][Full Text] [Related]
2. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.
Mrózek K; Döhner H; Bloomfield CD
Curr Opin Hematol; 2007 Mar; 14(2):106-14. PubMed ID: 17255787
[TBL] [Abstract][Full Text] [Related]
3. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
4. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
5. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
Verhaak RG; Goudswaard CS; van Putten W; Bijl MA; Sanders MA; Hugens W; Uitterlinden AG; Erpelinck CA; Delwel R; Löwenberg B; Valk PJ
Blood; 2005 Dec; 106(12):3747-54. PubMed ID: 16109776
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review.
Baldus CD; Mrózek K; Marcucci G; Bloomfield CD
Br J Haematol; 2007 Jun; 137(5):387-400. PubMed ID: 17488484
[TBL] [Abstract][Full Text] [Related]
7. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia.
Mrózek K; Bloomfield CD
Hematology Am Soc Hematol Educ Program; 2006; ():169-77. PubMed ID: 17124057
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
9. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.
Baldus CD; Thiede C; Soucek S; Bloomfield CD; Thiel E; Ehninger G
J Clin Oncol; 2006 Feb; 24(5):790-7. PubMed ID: 16418499
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of combined IDH1 and NPM1 mutations in the intermediate cytogenetic de novo acute myeloid leukemia.
Abd El-Lateef AE; Ismail MM; Almohammadi M; Gawaly AM
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):92-98. PubMed ID: 34933728
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.
Gaidzik V; Döhner K
Semin Oncol; 2008 Aug; 35(4):346-55. PubMed ID: 18692685
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
Cao L; Zhang W; Liu X; Yang P; Wang J; Hu K; Zhang X; Liu W; He X; Jing H; Yuan X
Sci Rep; 2019 Nov; 9(1):16991. PubMed ID: 31740742
[TBL] [Abstract][Full Text] [Related]
13. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
Radmacher MD; Marcucci G; Ruppert AS; Mrózek K; Whitman SP; Vardiman JW; Paschka P; Vukosavljevic T; Baldus CD; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD;
Blood; 2006 Sep; 108(5):1677-83. PubMed ID: 16670265
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
Marcucci G; Baldus CD; Ruppert AS; Radmacher MD; Mrózek K; Whitman SP; Kolitz JE; Edwards CG; Vardiman JW; Powell BL; Baer MR; Moore JO; Perrotti D; Caligiuri MA; Carroll AJ; Larson RA; de la Chapelle A; Bloomfield CD
J Clin Oncol; 2005 Dec; 23(36):9234-42. PubMed ID: 16275934
[TBL] [Abstract][Full Text] [Related]
15. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
16. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
Marcucci G; Mrózek K; Bloomfield CD
Curr Opin Hematol; 2005 Jan; 12(1):68-75. PubMed ID: 15604894
[TBL] [Abstract][Full Text] [Related]
17. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
18. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD; Bullinger L
Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
[TBL] [Abstract][Full Text] [Related]
19. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
